Ex vivo expansion of hematopoietic stem cells

JingJing J. Xie, Chengcheng Zhang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Ex vivo expansion of hematopoietic stem cells (HSCs) would benefit clinical applications in several aspects, to improve patient survival, utilize cord blood stem cells for adult applications, and selectively propagate stem cell populations after genetic manipulation. In this review we summarize and discuss recent advances in the culture systems of mouse and human HSCs, which include stroma/HSC co-culture, continuous perfusion and fed-batch cultures, and those supplemented with extrinsic ligands, membrane transportable transcription factors, complement components, protein modification enzymes, metabolites, or small molecule chemicals. Some of the expansion systems have been tested in clinical trials. The optimal condition for ex vivo expansion of the primitive and functional human HSCs is still under development. An improved understanding of the mechanisms for HSC cell fate determination and the HSC culture characteristics will guide development of new strategies to overcome difficulties. In the future, development of a combination treatment regimen with agents that enhance self-renewal, block differentiation, and improve homing will be critical. Methods to enhance yields and lower cost during collection and processing should be employed. The employment of an efficient system for ex vivo expansion of HSCs will facilitate the further development of novel strategies for cell and gene therapies including genome editing.

Original languageEnglish (US)
Pages (from-to)839-853
Number of pages15
JournalScience China Life Sciences
Volume58
Issue number9
DOIs
StatePublished - Sep 1 2015

Fingerprint

Hematopoietic Stem Cells
Stem cells
stem
Cell culture
stem cells
Stem Cells
Cell Culture Techniques
Batch Cell Culture Techniques
gene therapy
Population Genetics
coculture
blood cells
Cell- and Tissue-Based Therapy
Coculture Techniques
hematopoietic stem cells
Gene therapy
Fetal Blood
genetic engineering
Genetic Therapy
ligand

Keywords

  • cord blood
  • CRISPR/Cas9
  • ex vivo expansion
  • genome editing
  • hematopoietic stem cells
  • niche
  • SCID-repopulating cell
  • signal transduction
  • transplantation

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Environmental Science(all)

Cite this

Ex vivo expansion of hematopoietic stem cells. / Xie, JingJing J.; Zhang, Chengcheng.

In: Science China Life Sciences, Vol. 58, No. 9, 01.09.2015, p. 839-853.

Research output: Contribution to journalArticle

Xie, JingJing J. ; Zhang, Chengcheng. / Ex vivo expansion of hematopoietic stem cells. In: Science China Life Sciences. 2015 ; Vol. 58, No. 9. pp. 839-853.
@article{5231e76e8cc34ff9b6807f44a70ce2ec,
title = "Ex vivo expansion of hematopoietic stem cells",
abstract = "Ex vivo expansion of hematopoietic stem cells (HSCs) would benefit clinical applications in several aspects, to improve patient survival, utilize cord blood stem cells for adult applications, and selectively propagate stem cell populations after genetic manipulation. In this review we summarize and discuss recent advances in the culture systems of mouse and human HSCs, which include stroma/HSC co-culture, continuous perfusion and fed-batch cultures, and those supplemented with extrinsic ligands, membrane transportable transcription factors, complement components, protein modification enzymes, metabolites, or small molecule chemicals. Some of the expansion systems have been tested in clinical trials. The optimal condition for ex vivo expansion of the primitive and functional human HSCs is still under development. An improved understanding of the mechanisms for HSC cell fate determination and the HSC culture characteristics will guide development of new strategies to overcome difficulties. In the future, development of a combination treatment regimen with agents that enhance self-renewal, block differentiation, and improve homing will be critical. Methods to enhance yields and lower cost during collection and processing should be employed. The employment of an efficient system for ex vivo expansion of HSCs will facilitate the further development of novel strategies for cell and gene therapies including genome editing.",
keywords = "cord blood, CRISPR/Cas9, ex vivo expansion, genome editing, hematopoietic stem cells, niche, SCID-repopulating cell, signal transduction, transplantation",
author = "Xie, {JingJing J.} and Chengcheng Zhang",
year = "2015",
month = "9",
day = "1",
doi = "10.1007/s11427-015-4895-3",
language = "English (US)",
volume = "58",
pages = "839--853",
journal = "Science China. Life sciences",
issn = "1674-7305",
publisher = "Science in China Press",
number = "9",

}

TY - JOUR

T1 - Ex vivo expansion of hematopoietic stem cells

AU - Xie, JingJing J.

AU - Zhang, Chengcheng

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Ex vivo expansion of hematopoietic stem cells (HSCs) would benefit clinical applications in several aspects, to improve patient survival, utilize cord blood stem cells for adult applications, and selectively propagate stem cell populations after genetic manipulation. In this review we summarize and discuss recent advances in the culture systems of mouse and human HSCs, which include stroma/HSC co-culture, continuous perfusion and fed-batch cultures, and those supplemented with extrinsic ligands, membrane transportable transcription factors, complement components, protein modification enzymes, metabolites, or small molecule chemicals. Some of the expansion systems have been tested in clinical trials. The optimal condition for ex vivo expansion of the primitive and functional human HSCs is still under development. An improved understanding of the mechanisms for HSC cell fate determination and the HSC culture characteristics will guide development of new strategies to overcome difficulties. In the future, development of a combination treatment regimen with agents that enhance self-renewal, block differentiation, and improve homing will be critical. Methods to enhance yields and lower cost during collection and processing should be employed. The employment of an efficient system for ex vivo expansion of HSCs will facilitate the further development of novel strategies for cell and gene therapies including genome editing.

AB - Ex vivo expansion of hematopoietic stem cells (HSCs) would benefit clinical applications in several aspects, to improve patient survival, utilize cord blood stem cells for adult applications, and selectively propagate stem cell populations after genetic manipulation. In this review we summarize and discuss recent advances in the culture systems of mouse and human HSCs, which include stroma/HSC co-culture, continuous perfusion and fed-batch cultures, and those supplemented with extrinsic ligands, membrane transportable transcription factors, complement components, protein modification enzymes, metabolites, or small molecule chemicals. Some of the expansion systems have been tested in clinical trials. The optimal condition for ex vivo expansion of the primitive and functional human HSCs is still under development. An improved understanding of the mechanisms for HSC cell fate determination and the HSC culture characteristics will guide development of new strategies to overcome difficulties. In the future, development of a combination treatment regimen with agents that enhance self-renewal, block differentiation, and improve homing will be critical. Methods to enhance yields and lower cost during collection and processing should be employed. The employment of an efficient system for ex vivo expansion of HSCs will facilitate the further development of novel strategies for cell and gene therapies including genome editing.

KW - cord blood

KW - CRISPR/Cas9

KW - ex vivo expansion

KW - genome editing

KW - hematopoietic stem cells

KW - niche

KW - SCID-repopulating cell

KW - signal transduction

KW - transplantation

UR - http://www.scopus.com/inward/record.url?scp=84942992157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942992157&partnerID=8YFLogxK

U2 - 10.1007/s11427-015-4895-3

DO - 10.1007/s11427-015-4895-3

M3 - Article

C2 - 26246379

AN - SCOPUS:84942992157

VL - 58

SP - 839

EP - 853

JO - Science China. Life sciences

JF - Science China. Life sciences

SN - 1674-7305

IS - 9

ER -